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Background
The development of an effective vaccine against all strains 
of  Neisseria  meningitidis  (meningococcus),  the  major 
cause  of  life-threatening  bacterial  meningitis  and 
septicemia, is a priority for infectious disease research. 
Meningococci can be classified into serogroups based on 
the structure of their extracellular capsular polysac  cha-
ride,  with  serogroups  B  and  C  being  traditionally  res-
ponsible  for  the  majority  of  invasive  disease  in  most 
temperate countries, and serogroup A causing epidemic 
infections in sub-Saharan Africa.
The  first  generation  of  vaccines  contained  purified 
polysaccharides from serogroups A and C that induced 
antibodies that promoted complement-mediated serum 
bactericidal  activity  (SBA),  the  correlate  of  protective 
immunity, against the respective serogroups. Tetravalent 
polysaccharide  vaccines  were  later  produced  by  the 
addition  of  serogroups  Y  and  W135.  However,  such 
vaccines  suffer  from  poor  immunogenicity  as  a  conse-
quence  of  the  inability  of  polysaccharide  antigens  to 
induce an effective T-helper-cell response. In adults, they 
produce only a short-lived antibody response and fail to 
induce  immunological  memory.  Furthermore,  they  are 
non-immunogenic in infants, the main potential target 
group  for  meningococcal  vaccines.  Second-generation 
vaccines  were  subsequently  developed  in  which  the 
capsular polysaccharides were covalently linked to carrier 
proteins in order to induce a T-helper-cell response. Such 
polysaccharide  vaccines  produce  a  long-lived  IgG 
response  and  induce  immunological  memory  even  in 
infants. The first such vaccine, a serogroup C conjugate, 
was introduced into the UK immunization program in 
1999 and has been extremely effective in reducing cases 
of serogroup C infections [1].
Unfortunately, none of the above strategies have been 
applicable to infection caused by serogroup B meningo-
cocci,  which  is  the  major  serogroup  associated  with 
invasive  disease  in  most  western  countries.  The  sero-
group  B  capsular  polysaccharide  is  non-immunogenic 
even in adults, due to molecular mimicry of neural cell 
adhesion molecules expressed on developing fetal brain 
tissue  [2].  Alternative  strategies  have  focused  on  the 
vaccine potential of subcapsular antigens. Experimental 
vaccines  have  been  based  on  outer  membrane  (OM) 
‘blebs’ released from the surface of meningococci during 
growth  and  from  which  toxic  lipopolysaccharide  has 
been selectively removed by extraction with deoxycholate 
detergent. Such outer membrane vesicle (OMV) vaccines 
have  been  used  in  attempts  to  control  outbreaks  of 
serogroup B infection in countries such as Norway, Cuba 
and New Zealand when epidemics have been caused by 
one predominant serosubtype [3-5]. The success of such 
Abstract
There is a particular need for an effective vaccine 
against life-threatening meningitis and septicemia 
caused by Neisseria meningitidis (meningococcus) 
serogroup B strains. Vaccine strategies incorporating 
capsular polysaccharide have proved effective 
against other meningococcal serogroups, but are not 
applicable to serogroup B. Attention has therefore 
focused on the subcapsular outer membrane 
protein antigens as potential vaccine components. 
The sequencing of genomes from three serogroups 
and the availability of the corresponding translated 
protein databases, combined with the development 
of sensitive proteomic techniques, have opened up 
new avenues of meningococcal vaccine research. This 
has resulted in the identification of potential candidate 
antigens for incorporation into multicomponent 
meningococcal vaccines.
© 2010 BioMed Central Ltd
The influence of genomics and proteomics on 
the development of potential vaccines against 
meningococcal infection
John E Heckels*† and Jeannette N Williams†
REVIEW
*Correspondence: jeh@soton.ac.uk 
Molecular Microbiology Group, Sir Henry Wellcome Laboratories, Division of 
Infection, Inflammation and Immunity, University of Southampton Faculty of 
Medicine, Mailpoint 814, Southampton General Hospital, Southampton SO16 6YD, 
UK 
†Contributed equally
Heckels and Williams Genome Medicine 2010, 2:43 
http://genomemedicine.com/content/2/7/43
© 2010 BioMed Central Ltdvaccines has been limited by problems, including: a short 
duration of protection, poor immunogenicity in children, 
and  variable  responses  in  individuals  to  the  different 
proteins present in the vesicles [6,7]. Furthermore, the 
main protective component is believed to be the PorA 
outer  membrane  protein  [8],  which  varies  between 
strains and so generates a large number of serosubtype 
differences  that  are  expressed  independently  of  sero-
group. The immunity induced is therefore largely serosub-
type  specific,  and  a  vaccine  based  on  such  a  strategy 
would  necessarily  have  to  be  prepared  from  multiple 
strains  and  the  composition  tailored  for  geographical 
location and adjusted over time to match the changing 
incidence of serosubtypes [9].
An effective vaccine against serogroup B meningococci 
should induce immunity against strains of a wide range of 
serosubtypes. The contribution of the PorA protein to the 
protective effect of OMV vaccines is illustrated by the 
predominantly  serosubtype  specificity  of  the  resulting 
SBA. However, analysis of the immune response to OMV 
vaccines  [10,11]  and  studies  of  the  development  of 
natural immunity induced by colonization with meningo-
cocci [12] have suggested that a minor component of the 
SBA is cross-reactive against heterologous serosubtypes. 
Unfortunately, at the time of these studies, the limitations 
of  available  technology  meant  that  the  identity  of  the 
antigen(s) responsible for potential cross-reactive immu-
nity could not be determined.
Genomic approaches
The  search  for  meningococcal  antigens  capable  of 
inducing  cross-reactive  immunity  has  been  revolution-
ized by the availability of complete genome sequences, 
and the resulting predicted proteins, from meningococcal 
strains of serogroups A, B and C [13-15].
The first approach has been the use of in silico analysis 
of the predicted proteome of serogroup B strain MC58 to 
identify putative candidate vaccine antigens; this approach 
has  been  dubbed  ‘reverse  vaccinology’.  Pizza  and 
colleagues  [16]  identified  570  potential  open  reading 
frames  that  encode  proteins  predicted  to  be  either 
surface exposed or exported from the bacteria, and they 
were  able  to  express  350  of  these  as  fusion  proteins. 
Antisera  raised  against  these  proteins  were  tested  for 
SBA and cross-reactivity, leading to the identification of 
seven proteins as potential vaccine antigens. Five of these 
were chosen for large-scale expression and incorporated 
into  an  experimental  human  vaccine.  Immunization  of 
mice with the pentavalent vaccine induced a bactericidal 
immune response against a range of strains tested [17]. 
Phase  III  clinical  trials  are  underway  with  a  similar 
vaccine that additionally incorporates OMV [18]. Subse-
quently,  genome  sequences  of  other  Neisseria  species 
have  become  available,  and  Pajon  and  colleagues  [19] 
have  exploited  these  together  with  a  more  intensive 
bioinformatic  approach  to  identify  five  additional 
antigens  that  are  also  able  to  induce  a  bactericidal 
immune response to meningococci.
Proteomic analysis
The  availability  of  genome  sequences  and  the  corres-
pond  ing  translated  protein  databases  have  enabled 
studies on the meningococcal proteome, particularly the 
detailed  composition  of  outer  membrane  fractions.  In 
early  studies,  Frasch  and  colleagues  [20]  were  able  to 
distinguish only five major classes of proteins in outer 
membrane  preparations  from  meningococci.  Subse-
quently,  additional  proteins  were  identified  that  were 
present  in  lower  amounts  or  only  expressed  when  the 
bacteria  had  been  grown  under  nutrient  limitation 
(reviewed in [21]). The total number of proteins identified 
in outer membrane preparations remained relatively few 
until  the  development  of  more  sensitive  proteomic 
methods.  This  combined  with  the  availability  of  the 
trans  lated  genome  sequences  has  enabled  much  more 
detailed study of outer membrane preparations and the 
vesicle/vaccine  preparations  derived  from  them  by 
deoxycholate extraction. One-dimensional SDS-PAGE of 
an OMV vaccine preparation followed by tandem mass 
spectrometry (MS/MS) identified 40 proteins, including 
7 that had previously been identified as vaccine candi-
dates [22]. Replacing SDS-PAGE with two-dimensional 
electrophoresis increased the number of proteins identi-
fied to 74 [23].
Further  sensitivity  can  be  obtained  using  SDS-PAGE 
and nanocapillary liquid chromatography-tandem mass 
spectrometry (GeLC-MS/MS). Proteins are separated on 
a conventional one-dimensional SDS-PAGE gel, which is 
then cut into slices that are subjected to in situ proteolytic 
digestion.  The  resulting  peptides  are  separated  by 
reverse-phase liquid chromatography and then applied to 
a tandem mass spectrometer. Proteins are identified by 
comparison  of  the  peptide  fragments  with  the  sixfold 
translated genome database. This technique overcomes 
the  problems  of  two-dimensional  gels  associated  with 
poor solubility of membrane proteins and has the addi-
tional  advantage  of  providing  an  indication  of  relative 
abundance based on the number of peptide fragments 
identified per protein. Using this technique, Vaughan et 
al.  [24]  identified  125  potential  proteins  in  an  OMV 
vaccine  and  noted  significant  differences  in  a  similar 
preparation  from  the  related  non-pathogen  Neisseria 
lactamica,  which  has  been  suggested  as  an  alternative 
vaccine. Williams et al. [25] used GeLC-MS/MS to com-
pare an OM preparation with the corresponding OMV 
vaccine preparation obtained by deoxycholate extraction. 
A  total  of  236  proteins  were  identified  in  the  OM 
preparation, and the PSORTb algorithm [26] was used to 
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the  identified  proteins  were  predicted  to  have  an  OM 
location but these included all of those well established as 
major components of the outer membrane. The proteins 
not  predicted  to  have  an  OM  location  were  predomi-
nantly periplasmic, cytoplasmic, or of unknown location, 
while relatively few cytoplasmic membrane proteins were 
detected. The major proteins present were those that had 
previously been identified as the major components of 
the OM, including PorA, PorB, Opa, Opc, Rmp and PilQ. 
Interestingly, several proteins that had previously been 
suggested  as  potential  vaccine  candidates  were  not 
detected  in  either  OM  or  OMV  preparations;  these 
included  AspA,  GNA2132,  NadA,  and  GNA2001.  It  is 
not possible to determine whether the ‘non-OM proteins’ 
detected  in  the  preparations  occur  in  a  natural 
association  with  the  OM  or  whether  they  arise  by 
‘contami  nation’  during  the  isolation  process.  However, 
proteomic  analysis  has  shown  that  they  are  certainly 
present  in  the  OMV  vaccines  that  have  been  used  for 
human immunization [22,25].
An  alternative  strategy  to  the  use  of  deoxycholate  to 
deplete toxic lipopolysaccharide from OM preparations is 
to produce OM from a lipopolysaccharide-deficient mutant. 
Proteomic analysis of such a preparation by GeLC-MS/MS 
revealed  significant  differences  from  OMV  prepared 
conventionally  with  increased  levels  of  several  non-
membrane proteins, particularly those of the tricar  boxylic 
acid cycle [25]. The possible effects of these differ  ences in 
protein content between the two vaccines are unknown.
Immunoproteomics
The ability to combine the proteomic approach with the 
availability  of  animal  or  human  sera  with  known 
bactericidal activity has facilitated an immunoproteomic 
approach  to  the  identification  of  possible  vaccine 
candidates.
Mendum  et  al.  [27]  used  two-dimensional  immuno-
blotting  to  identify  antigens  recognized  by  sera  from 
patients  recovering  from  meningococcal  infection.  A 
total  of  33  proteins  were  identified  that  reacted  with 
acute  and/or  convalescent  sera,  although  it  was  not 
possible to correlate protein reactivity with the bacteri-
cidal activity of the sera. Twenty-seven of these proteins 
were produced in Escherichia coli and used for immuni-
zation of mice with Freund’s adjuvant. Although none of 
the resulting sera showed bactericidal activity, this may 
be due to a failure to refold the recombinant proteins into 
a native conformation, since the antigen list contained 
PorA protein, which others have shown to induce high 
levels of bactericidal activity after refolding into liposomes.
In  a  similar  two-dimensional  immunoblotting  study, 
Williams et al. [25] were able to utilize a panel of sera 
with  known  bactericidal  activity  and  corresponding 
colonizing strains from a longitudinal study of meningo-
coccal carriage in new students entering a university hall 
of  residence.  Individuals  who  became  colonized  with 
serogroup  B  meningococci  developed  bactericidal 
activity  not  only  against  the  homologous  colonizing 
strain but also against heterologous strains. Paired sera 
from  colonized  individuals  were  analyzed  by  immuno-
proteomic analysis using both homologous and hetero  lo-
gous OM preparations. Immunoblots were reacted with 
sera,  at  a  standard  dilution,  taken  from  the  individual 
pre-colonization and post-colonization. In each case the 
raised  bactericidal  antibody  activity  was  always 
associated with increased reactivity, but the number and 
intensity of reactions to different meningococcal proteins 
varied between students and between strains. Proteins on 
the reference gel were matched to the immunoreactive 
spots, excised, digested with trypsin, subjected to MS/
MS, and identified by searching against a translation of 
the MC58 genome. This resulted in the identification of 
43  proteins,  which  included  well-established  antigens 
such as PorA and PorB, as well as novel proteins. Such 
proteins  associated  with  the  development  of  cross-
reactive immunity to serogroup B meningococcal infec-
tion represent potential targets for the development of 
effective  vaccines  against  serogroup  B  meningococcal 
infection [28]. Previous studies with both PorA and PorB 
produced  as  recombinant  proteins  and  refolded  into 
liposomes  have  demonstrated  their  ability  to  induce 
serum  bactericidal  activity  against  homologous  strains 
[29,30]. Similar studies with the newly identified vaccine 
candidates  will  reveal  their  potential  for  inducing  a 
potentially protective and cross-reacting immune response 
against serogroup B (and other serogroup) meningococci.
Conclusions
The  sequencing  of  meningococcal  genomes  and  the 
availability of the corresponding protein databases, com-
bined with sensitive modern technology, have opened up 
exciting new avenues in meningococcal vaccine research. 
At least one vaccine based on information gleaned from 
proteomics  and  genomics  is  undergoing  clinical  trials 
[18] and others are currently being planned. It is likely 
that these technologies will continue to inform the field 
in  the  identification  of  proteins  associated  with  the 
development of immunity and in the elucidation of their 
role  in  pathogenesis  of  meningococcal  infection. 
Hopefully, these approaches will bear fruit in the search 
for an effective vaccine against a devastating infection.
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